Diabetes Research and Clinical Practice
Volume 76, Issue 2 , Pages 199-206 , May 2007

Changes of osteoprotegerin before and after insulin therapy in type 1 diabetic patients

Received 19 June 2006 ,Accepted 4 September 2006.

References 

  1. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang M-S, Lüthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89:309–319
  2. Hsu H, Lacey DL, Dunstan CR, Solovyew I, Colombero A, Timms E, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc. Natl. Acad. Sci. U.S.A. 1999;96:3545–3549
  3. Dhore CR, Cleutjens JP, Lutgens E, Cleutjens KB, Geusens PP, Kitslaar PJ, et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscl. Throm. Vasc. Biol. 2001;21:1998–2003
  4. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998;12:1260–1268
  5. Zhang J, Fu M, Myles D, Zhu X, Du J, Cao X, et al. PDGF induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathways. FEBS Lett. 2002;521:180–184
  6. Malyankar UM, Scatena M, Suchland KL, Yun TJ, Clark EA, Giachelli CM. Osteoprotegerin is an alpha beta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. J. Biol. Chem. 2000;275:20959–20962
  7. Jono S, Ikari Y, Shioi A, Mori K, Miki T, Hara K, et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation. 2002;106:1192–1194
  8. Schoppet M, Sattler AM, Schaefer JR, Herzum M, Maisch B, Hofbauer LC. Increased osteoprotegerin serum levels in men with coronary artery disease. J. Clin. Endocrinol. Metab. 2003;88:1024–1028
  9. Knudsen ST, Foss CH, Poulsen PL, Andersen NH, Mogensen CE, Rasmussen LM. Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. Eur. J. Endocrinol. 2003;149:39–42
  10. Avignon A, Sultan A, Piot C, Elaerts S, Cristol JP, Dupuy AM. Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients. Diabetes Care. 2005;28:2176–2180
  11. Xiang GD, Xu L, Zhao LS, Yue L, Hou J. The relationship between plasma osteoprotegerin and endothelium-dependent arterial dilation in type 2 diabetes. Diabetes. 2006;55:2126–2131
  12. Galluzzi F, Stagi S, Salti R, Toni S, Piscitelli E, Simonini G, et al. Osteoprotegerin serum levels in children with type 1 diabetes: a potential modulating role in bone status. Eur. J. Endocrinol. 2005;153:879–885
  13. Boneti PO, Lerman LO, Lerman A. Endothelial dysfunction, a marker of atherosclerotic risk. Arterioscler. Thromb. Vasc. Biol. 2003;23:168–175
  14. Xiang GD, Wu YH. Apolipoprotein e4 allele and endothelium-dependent arterial dilation in type 2 diabetes mellitus without angiopathy. Diabetologia. 2003;46:514–519
  15. Xiang GD, Wang YL. Regular aerobic exercise training improves endothelium-dependent artery dilation in patients with impaired fasting glucose. Diabetes Care. 2004;27:801–802
  16. Olesen P, Ledet T, Rasmussen LM. Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-alpha. Diabetologia. 2005;48:561–568
  17. Browner WS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J. Clin. Endocrinol. Metab. 2001;86:631–637
  18. Ueland T, Jemtland R, Godang K, Kjekshus J, Hognestad A, Omland T, et al. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J. Am. College Cardiol. 2004;44:1970–1976
  19. Rasmussen LM, Tarnow L, Hansen TK, Parving HH, Flyvbjerg A. Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients. Eur. J. Endocrinol. 2006;154:75–81
  20. Hofbauer LC, Schoppet M. Osteoprotegerin: a link between osteoporosis and arterial calcification?. Lancet. 2001;358:257–259
  21. Chan NN, Vallance P, Colhoun HM. Nitric oxide and vascular responses in type 1 diabetes. Diabetologia. 2000;43:137–147
  22. Donaghue KC, Robinson J, McCredie R, Fung A, Silink M, Celermajer DS. Large vessel dysfunction in diabetic adolescents and its relationship to small vessel complications. J. Pediatr. Endocrinol. Metab. 1997;10:593–598
  23. Wiltshire EJ, Gent R, Hirte C, Pena A, Thomas DW, Couper SS. Endothelial dysfunction relates to folate status in children and adolescents with type 1 diabetes. Diabetes. 2002;51:2282–2286
  24. Järvisalo MJ, Raitakari M, Toikka JO, Putto-Laurila A, Rontu R, Laine S, et al. Endothelial dysfunction and increased arterial intima-media thickness in children with type 1 diabetes. Circulation. 2004;109:1750–1755
  25. Kim SM, Leet J, Ryu OH, Lee KW, Kim HY, Seo JA, et al. Serum osteoprotegerin levels are associated with inflammation and pulse wave velocity. Clin. Endocrinol. 2005;63:594–598
  26. Buzi F, Maccarinelli G, Guaragni B, Ruggeri F, Radetti G, Meini A, et al. Serum osteoprotegerinand receptor activator of nuclear factors kB (RANK) concentrations in normal children and in children with pubertal precocity, Turner's syndrome and rheumatoid arthritis. Clin. Endocrinol. 2004;60:87–91
  27. Kiechl S, Schett G, Wenning G, Redlich K, Oberhollenzer M, Mayr A, et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation. 2004;109:2175–2180
  28. Rhee EJ, Lee WY, Kim SY, Kim BJ, Sung KC, Kim BS, et al. Relationship of serum osteoprotegerin levels with coronary artery disease severity, left ventricular hypertrophy and C-reactive protein. Clin. Sci. 2005;108:237–243
  29. Cosson E, Pham I, Valens P, Parries J, Attali JR, Nitenberg A. Impaired coronary endothelium-dependent vasodilation is associated with microalbuminuria in type 2 diabetes and angiographically normal coronary arteries. Diabetes Care. 2006;29:107–112
  30. Diercks GF, van Boven AJ, Hillege JL, de Jong PE, Rouleau JL, van Gilst WH. The importance of microalbuminuria as a cardiovascular risk indicator. Can. J. Cardiol. 2002;18:525–535
  31. Szulc P, Hofbauer LC, Heufelder AE, Roth S, Delmas PD. Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone. J. Clin. Endocrinol. Metab. 2001;86:3162–3165

PII: S0168-8227(06)00392-5

doi: 10.1016/j.diabres.2006.09.008

Diabetes Research and Clinical Practice
Volume 76, Issue 2 , Pages 199-206 , May 2007

Article Tools

* Image Usage & Resolution